Literature DB >> 10807407

A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.

N Yoshida1, T Yoshikawa, Y Tanaka, N Fujita, K Kassai, Y Naito, M Kondo.   

Abstract

BACKGROUND: Neutrophil-endothelial cell interactions mediated by adhesion molecules may be involved in gastric mucosal inflammation associated with Helicobacter pylori or nonsteroidal anti-inflammatory drugs. AIM: To investigate the effects of proton pump inhibitors and histamine-2 receptor antagonists (HRA) on neutrophil-endothelial cell adhesive interactions induced by H. pylori water extract (HPE) or interleukin-1beta (IL-1beta).
METHODS: Human peripheral neutrophils and umbilical vein endothelial cells were incubated with either proton pump inhibitors (lansoprazole and omeprazole) or HRA (famotidine and ranitidine). Neutrophil surface expression of CD11b and CD18 and endothelial cell intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) were assessed by flow cytometry and an enzyme immunoassay, respectively. Neutrophil adherence was defined as the ratio of exogenous neutrophils that adhered to the endothelial monolayers.
RESULTS: The expression of CD11b and CD18 on neutrophils and neutrophil-dependent adhesion to endothelial cells elicited by HPE were inhibited by lansoprazole and omeprazole at clinical relevant doses, and the expression of ICAM-1 and VCAM-1 on endothelial cells and endothelial-dependent neutrophil adherence induced by IL-1beta were also inhibited by lansoprazole and omeprazole at similar doses. Famotidine and ranitidine had no effect on neutrophil-endothelial cell interactions.
CONCLUSIONS: These results indicate that proton pump inhibitors can attenuate neutrophil adherence to endothelial cells via inhibiting the expression of adhesion molecules, suggesting that proton pump inhibitors may have anti-inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807407     DOI: 10.1046/j.1365-2036.2000.014s1074.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  65 in total

1.  Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.

Authors:  Janet T Holbrook; Robert A Wise; Benjamin D Gold; Kathryn Blake; Ellen D Brown; Mario Castro; Allen J Dozor; John J Lima; John G Mastronarde; Marianna M Sockrider; W Gerald Teague
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

2.  Omeprazole Attenuates Pulmonary Aryl Hydrocarbon Receptor Activation and Potentiates Hyperoxia-Induced Developmental Lung Injury in Newborn Mice.

Authors:  Binoy Shivanna; Shaojie Zhang; Ananddeep Patel; Weiwu Jiang; Lihua Wang; Stephen E Welty; Bhagavatula Moorthy
Journal:  Toxicol Sci       Date:  2015-08-13       Impact factor: 4.849

3.  A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection.

Authors:  Yong Gil Kim; Byung-Ik Jang; Tae Nyeun Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

Review 4.  Present status and strategy of NSAIDs-induced small bowel injury.

Authors:  Kazuhide Higuchi; Eiji Umegaki; Toshio Watanabe; Yukiko Yoda; Eijiro Morita; Mitsuyuki Murano; Satoshi Tokioka; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2009-07-01       Impact factor: 7.527

5.  Eosinophilic esophagitis: interactions with gastroesophageal reflux disease.

Authors:  Edaire Cheng; Rhonda F Souza; Stuart Jon Spechler
Journal:  Gastroenterol Clin North Am       Date:  2014-03-24       Impact factor: 3.806

6.  In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-κB and activator protein-1.

Authors:  Xiaofang Huo; Xi Zhang; Chunhua Yu; Qiuyang Zhang; Edaire Cheng; David H Wang; Thai H Pham; Stuart J Spechler; Rhonda F Souza
Journal:  Gut       Date:  2013-09-18       Impact factor: 23.059

7.  Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats.

Authors:  Hiroshi Ichikawa; Norimasa Yoshida; Tomohisa Takagi; Naoya Tomatsuri; Kazuhiro Katada; Yutaka Isozaki; Kazuhiko Uchiyama; Yuji Naito; Takeshi Okanoue; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

8.  The expression of heme oxygenase-1 induced by lansoprazole.

Authors:  Tomohisa Takagi; Yuji Naito; Toshikazu Yoshikawa
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

9.  Prevention of NSAID-Induced Small Intestinal Mucosal Injury: Prophylactic Potential of Lansoprazole.

Authors:  Kazuhide Higuchi; Yukiko Yoda; Kikuko Amagase; Shinichi Kato; Satoshi Tokioka; Mitsuyuki Murano; Koji Takeuchi; Eiji Umegaki
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

10.  Effects of Lansoprazole on the Lipopolysaccharide-Stimulated Toll-Like Receptor 4 Signal Transduction Systems: A Study Using the 293hTLR4/MD2-CD14 Cells.

Authors:  Tadashi Ohara; Yuhsaku Kanoh; Keiichi Yoshino; Masaki Kitajima
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.